To investigate the detailed molecular mechanism of mammary carcinogenesis and discover novel therapeutic targets, we previously analysed gene expression profiles of breast cancers. We here report characterization of a significant role of DTL/RAMP (denticleless/RA-regulated nuclear matrix associated protein) in mammary carcinogenesis. Semiquantitative RT-PCR and northern blot analyses confirmed upregulation of DTL/RAMP in the majority of breast cancer cases and all of breast cancer cell lines examined. Immunocytochemical and western blot analyses using anti-DTL/RAMP polyclonal antibody revealed cell-cycle-dependent localization of endogenous DTL/RAMP protein in breast cancer cells; nuclear localization was observed in cells at interphase and the protein was concentrated at the contractile ring in cytokinesis process. The expression level of DTL/RAMP protein became highest at G 1 /S phases, whereas its phosphorylation level was enhanced during mitotic phase. Treatment of breast cancer cells, T47D and HBC4, with small-interfering RNAs against DTL/RAMP effectively suppressed its expression and caused accumulation of G 2 /M cells, resulting in growth inhibition of cancer cells. We further demonstrate the in vitro phosphorylation of DTL/ RAMP through an interaction with the mitotic kinase, Aurora kinase-B (AURKB). Interestingly, depletion of AURKB expression with siRNA in breast cancer cells reduced the phosphorylation of DTL/RAMP and decreased the stability of DTL/RAMP protein. These findings imply important roles of DTL/RAMP in growth of breast cancer cells and suggest that DTL/RAMP might be a promising molecular target for treatment of breast cancer.
Introduction
Breast cancer is the most common cancer in women, with estimated new cases of 1.15 million worldwide in 2002 (Parkin et al., 2005) . Incidence rates of breast cancer are increasing in most countries, and the increasing rate is much higher in countries where its incidence was previously low (Parkin et al., 2005) . Early detection with mammography as well as development of molecular targeted drugs such as tamoxifen and trastuzumab reduced the mortality rate and made the quality of life of the patients better (Bange et al., 2001; Navolanic and McCubrey, 2005) . However, still very limited treatment options are available to patients at an advanced stage, particularly those with a hormoneindependent tumor. Hence, development of novel drugs to provide better management to such patients is still eagerly expected.
Gene expression profiles obtained by cDNA microarray analysis have been proven to provide detailed characterization of individual cancers and such information should contribute to choose more appropriate clinical strategies to individual patients through development of novel drugs and providing the basis of personalized treatment (Petricoin et al., 2002) . Through the genome-wide expression analysis we have isolated a number of genes that function as oncogenes in the process of development and/or progression of breast cancers (Park et al., 2006; Lin et al., 2007; Shimo et al., 2007) , synovial sarcomas (Nagayama et al., 2004 (Nagayama et al., , 2005 and renal cell carcinomas (Togashi et al., 2005; Hirota et al., 2006) . Such molecules are considered to be candidate targets for development of new therapeutic modalities.
In an attempt to identify novel molecular targets for breast cancer therapy, we previously analysed the detailed gene-expression profiles of breast cancer cells, which were purified by laser microbeam microdissection, by means of cDNA microarray (Nishidate et al., 2004) . In this report we focused on characterization of a DTL/RAMP (denticleless/RA-regulated nuclear matrix associated protein) gene that was previously isolated as one of downregulated genes during retinoic acid-induced differentiation of human embryonal carcinoma cell line, NT2 cells (Cheung et al., 2001 ) to elucidate its pathophysiologic roles in growth of breast cancer cells.
Results

Overexpression of DTL/RAMP in breast cancer cells
We validated that the elevated the DTL/RAMP (denticleless/RA-regulated nuclear matrix associated protein) gene (GenBank accession no. NM_016448) expression in 10 of 12 clinical breast cancer cases by semiquantitative RT-PCR analysis ( Figure 1a ) as well as cDNA microarray data (Nishidate et al., 2004) . Subsequent northern blot analysis showed that an approximately 4.5-kb transcript of DTL/RAMP was significantly elevated in all of eight breast cancer cell lines examined (Figure 1b ), compared with normal breast. This transcript was most highly expressed in testis, and weakly expressed in bone marrow, thymus and placenta, but its expression was hardly detectable in any of the remaining normal organs we examined ( Figure 1c ).
To examine the expression of endogenous DTL/ RAMP protein, we generated a polyclonal antibody against DTL/RAMP protein and performed western blot analysis using cell lysates from eight breast cancer cell lines, HBC4, HBC5, HCC1937, MCF-7, MDA-MB-231, SK-BR-3, T47D and YMB-1. We confirmed a high level of DTL/RAMP protein expression in all the eight breast cancer cell lines examined, but its expression was hardly detectable in human mammalian epithelial cell (HMEC) cells (Figure 2a ). Additionally, we noticed two bands that reacted with anti-DTL/RAMP protein when a longer electrophoresis was performed. Therefore, to examine a possible modification of DTL/RAMP, we treated cellular extracts from T47D cells with lphosphatase and analysed the molecular weight of DTL/RAMP protein by western blot analysis. As the upper band was not observed when the cell extracts were incubated with phosphatase, we considered that the (16, 102, 247, 252, 302, 473, 478, 502, 552, 646, 769 and 779) , compared with normal human tissues (normal, microdissected normal breast ductal cells; MG, mammary gland) by semiquantitative RT-PCR. FDFT1 served as a loading control. (b) Northern blot analysis of the DTL/RAMP in eight breast cancer cell lines (HBC4, HBC5, HCC1937, MCF-7, MDA-MB-231, SK-BR-3, T47D and YMB-1) and normal human tissues including breast, lung, heart, liver, kidney and bone marrow. (c) Northern blot analysis of the DTL/RAMP transcript in various human tissues. PBL indicates peripheral blood leukocytes.
DTL/RAMP as a molecular-target for breast cancer T Ueki et al DTL/RAMP protein was possibly phosphorylated in breast cancer cells (Figure 2b ). Subsequently, to determine the phosphorylated region of the DTL/ RAMP protein, we made three constructs, each of which was designed to express a part of DTL/RAMP, and performed l-phosphatase assay ( Figure 2c , upper panel). The results revealed that the phosphorylation occurred in its C-terminal portion (438-730 amino acid; Figure 2c , lower panel).
Immunocytochemical-staining and immunohistochemicalstaining analyses
To characterize the biological role of DTL/RAMP, we first examined the subcellular localization of endogenous DTL/RAMP in HBC5 cells by immunocytochemical-staining analysis using an anti-DTL/RAMP polyclonal antibody (Figure 3a) . The endogenous DTL/ RAMP was mainly localized in the nucleus of interphase cells. After disappearance of nuclear membrane, the protein was stained diffusely within cells during prophase to metaphase. Subsequently, it accumulated as a series of narrow bars at spindle midzone in the anaphase cells and was finally concentrated at the contractile ring when cells were at telophase and cytokinesis stages. We investigated DTL/RAMP expression in clinical breast cancer and normal tissue sections by immunohistochemical staining. We identified positive staining of DTL/RAMP in the cytoplasm and nuclei of two different histological subtypes of breast cancer tissue sections, papillotubular carcinomas and scirrhous carcinomas, whereas no staining was observed in normal mammary tissues including ductal cells (no. 10441N; Figure 3b ). Furthermore, we performed breast cancer tissue-array analysis and verified positive staining of DTL/RAMP in 33 of 39 infiltrating ductal carcinomas, whereas no staining was observed in 5 normal mammary tissues including ductal cells (data not shown). Among the nine normal tissues we examined, its expression was detected in testis, but hardly detectable in heart, liver, kidney, lung, colon, pancreas, skeletal muscle and small intestine in concordance with the result of northern blot analysis (Figure 3c ).
Cell-cycle-dependent expression of DTL/RAMP
We performed fluorescence-activated cell sorting (FACS) and western blot analyses to examine the expression of DTL/RAMP protein at various cell-cycle phases using T47D cells after synchronization of the cell cycle by aphidicolin treatment. The results showed that the expression of DTL/RAMP was the highest at G 1 /S phase (0-6 h), and then strikingly reduced after G 2 /M phase (9-12 h) until next G 1 phase (12-30 h) (Figures 4a  and b) . Interestingly, a significant proportion of DTL/ RAMP protein was modified to the phosphorylated form during G 2 /M phase (9-12 h). Its phosphorylation level was gradually reduced from G 2 /M to G 1 phase (12-30 h; Figures 4a and b) . Furthermore, to examine the phosphorylation status and expression of DTL/ RAMP after mitotic phase in more detail, we synchronized T47D breast cancer cells with nocodazole, and confirmed the expression and phosphorylation of DTL/ RAMP in T47D breast cancer cells by western blot analysis using cells at mitotic phase collected by the DTL/RAMP as a molecular-target for breast cancer T Ueki et al mitotic shake-off method (Dechat et al., 1998 Furthermore, we examined morphological alterations of the T47D cells transfected with a DTL/RAMPspecific siRNA oligonucleotide (siDTL/RAMP), and confirmed the significant knockdown effect at the protein level ( Figure 5g ). Interestingly, we observed that its knockdown led to appearance of the intercellular bridges between two cells at a cell-division stage (Figure 5h ), indicating dysfunction at the late stage of cytokinesis process. We also observed enlargement of the size of the T47D cells transfected with siDTL/ RAMP in comparison with those transfected with control siEGFP (Figure 5h ). Additionally, we observed the similar morphological alterations in DTL/RAMPdepleted HBC4 breast cancer cells as well as T47D cells (Supplementary Figure 1) . Moreover, we confirmed that the midbody staining of DTL/RAMP protein was disappeared in DTL/RAMP-depleted HBC4 breast cancer cells, but was observed in control-siRNA-treated cells by immunochemical-staining analysis using DTL/ RAMP polycloncal antibody (Supplementary Figure 1) . To further evaluate the effect of DTL/RAMP depletion on cell cycle, we performed FACS analysis and confirmed that the proportion of cells at the G 2 /M phase was significantly higher for the cells treated with DTL/RAMP-siRNA (23.51%) than for those treated with EGFP-siRNA (13.77%; Figure 5i) To further confirm the growth promoting effect of DTL/RAMP, we established NIH3T3-derivative cells that stably expressed exogenous DTL/RAMP (DTL/ RAMP-1, -2, -3 and -4). Figure 6a showed that Flagtagged DTL/RAMP protein was observed at high level in these four derivate clones. Subsequent MTT assays showed that the four DTL/RAMP-stable derivative cells (DTL/RAMP-1, -2, -3 and -4) grew significantly faster than those transfected with mock plasmid (Mock-1, -2, and -3; Figure 6b ), suggesting a growth-enhancing effect of DTL/RAMP. These findings suggest that overexpression of DTL/RAMP might be involved in the growth of breast cancer cells. DTL/RAMP protein was regulated by Aurora kinase-B We described above the phosphorylation of DTL/ RAMP and its concentration at the contractile ring when cells were at telophase and cytokinesis stages in breast cancer cells. As Aurora kinase-B (AURKB) is known to be a chromosome passenger protein that moves from centrosomes to midzone spindle in anaphase and to the midbody in telophase and cytokinesis in HeLa cells (Adams et al., 2001; Terada, 2001; Carmena and Earnshaw, 2003) , we considered their similar subcellular localization at some cell-cycle phases.
In addition, we found six consensus phosphorylation sites for AURKB in full-length amino-acid sequence of DTL/RAMP protein according to previous reports Cheeseman et al., 2002; Ohashi et al., 2006) . Particularly, among them, five possible phosphorylation sites were found within the C-terminal region of DTL/RAMP (438-730 amino acid) where phosphorylation was observed (Figure 2c ). Hence, we examined a possible interaction of DTL/ RAMP protein with AURKB in breast cancer cells. We first compared the expression patterns of DTL/RAMP and AURKB by semiquantitative RT-PCR and western blot analysis, and confirmed the upregulation of both DTL/RAMP and AURKB in 7 of 12 breast cancer clinical cases and all of 8 breast cancer cell lines examined (Figures 7a and b) . Subsequently, we investigated an interaction between endogenous DTL/RAMP and AURKB proteins in T47D cells, in which these two proteins were expressed abundantly. Figure 7c shows that endogenous DTL/RAMP was coprecipitated with endogenous AURKB in breast cancer cells. Moreover, immunocytochemical-staining experiments confirmed both endogenous proteins colocalized at midbody in cytokinesis of T47D breast cancer cells (Figure 7d ). To further investigate whether DTL/RAMP is phosphorylated by AURKB, we performed in vitro kinase assay using a purified full-length DTL/RAMP (1-730 amino acids) recombinant protein and the full-length AURKB 
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T Ueki et al recombinant protein (see Materials and methods), and found phosphorylation of the DTL/RAMP protein by AURKB in vitro (Figure 7e ). On the other hand, we were unable to detect the phosphorylated DTL-RAMP protein by kinase-dead AURKB mutant (D200A; Figure 7e ). To further investigate a possible role of the interaction between DTL/RAMP and AURKB proteins and its phosphorylation by AURKB, we transfected siRNA-AURKB (siAURKB) into T47D cells, and then performed western blot and semiquantitative RT-PCR analyses. We observed the significant decrease of total DTL/RAMP protein as well as the phosphorylated DTL/RAMP protein in T47D cells transfected with siAURKB in comparison with those with a control siEGFP (Figure 7f) , whereas its transcriptional level was not reduced in AURKB-depleted cells. Furthermore, we found that the depletion of AURKB in T47D cells by siRNA induced accumulation of G 2 /M-arrested cells compared with treatment of a control-siEGFP (Supplementary Figure 2 ) as similar as the depletion of DTL/ RAMP (Figures 5g and i) . These findings suggested that endogenous DTL/RAMP may be stabilized in a late phase of mitosis when it is phosphorylated by AURKB or incorporated into some AURKB protein complex.
Discussion
Through identification and characterization of cancerrelated genes and their products, molecular targeting drugs for cancer therapy have been developed in the last two decades, but the proportion of patients who are able to have a benefit by presently available treatments is still very limited (Bange et al., 2001; Navolanic and McCubrey, 2005) . Therefore, it is urgent to develop new anticancer agents that will be highly specific to malignant cells and have the minimal risk of adverse reactions. In this study, we demonstrated the upregulation of DTL/RAMP in clinical breast cancer cases and cell lines, but was hardly detectable in any normal human tissues examined except a low level of expression in a few organs. DTL/RAMP gene encodes a putative 730-amino-acid protein that contains six highly conserved WD40-repeat domains and a consensus nuclear-localization signal at N terminus. Our results also demonstrated that DTL/ RAMP protein was mainly localized in the nucleus of interphase cells, accumulated as a series of narrow bars at spindle midzone in the anaphase cells, and was finally concentrated at the contractile ring in telophase and cytokinesis stages. These findings suggest the important role of this protein in cell-cycle progression.
We demonstrated by means of the siRNA technique that knocking down of the endogenous DTL/RAMP expression significantly suppressed the cell growth of breast cancer cell lines, T47D and HBC4, due to abnormal cell division and subsequent cell death, probably due to the dysfunction in the cytokinetic process. We have also demonstrated that the proportion of cells with a larger size was increased in the siDTL/ RAMP-transfected cells although we did not find an increase of the multinucleated cells. As it was reported that an inactivation of DTL/RAMP induced p53 stabilization in unstressed HeLa cells (Banks et al., 2006) , the accumulation of G 2 /M cells by knockdown of DTL/RAMP might be due to activation of the checkpoint system by p53 in breast cancer cell line T47D. Moreover, introduction of DTL/RAMP into NIH3T3 cells significantly enhanced cell growth. Hence, we further examined biological roles of DTL/RAMP in breast cancer cells by identification of its interacting protein(s).
Due to similarity of the subcellular localization at some cell-cycle phases and its coexpression in breast cancer cells, we focused on AURKB, serine/threonine kinase as a candidate for the DTL/RAMP interacting protein. We demonstrated the in vivo interaction and colocalization of DTL/RAMP with endogenous AURKB, and in vitro phosphorylation of DTL/RAMP as well as its possible stabilization by AURKB through the RNAi experiments although it remains to be x Axis indicates day points after the seeding and y axis indicates relative growth rate that was calculated in absorbance by comparison with the absorbance value of day 1 as a control. Assays were performed three times in triplicate wells.
DTL/RAMP as a molecular-target for breast cancer T Ueki et al elucidated whether DTL/RAMP is phosphorylated by AURKB in vivo. Additionally, it was reported that knockdown of AURKB also suppressed growth of HeLa cells because of cytokinesis defects (Severson et al., 2000; Goto et al., 2003) alike depletion of DTL/ RAMP. Together, we demonstrate here for the first time that interaction of DTL/RAMP and AURKB might play an important role in cytokinesis. Furthermore, DTL/RAMP is reported to be required in the initiation of a radiation-induced G 2 /M checkpoint as a component of the CUL4-DDB1 ubiquitin E3 ligase complex (Higa et al., 2006a, b; Sansam et al., 2006) , suggesting the multiple roles of DTL/RAMP in the cell-cycle progression. Taken together, as inhibition of their association may lead to cell death following the failure of cytokinesis in breast cancer cells, the inhibitor for their association would be a possible valuable target to develop agents against breast cancer. Furthermore, it is notable that our cDNA microarray data identified upregulation of DTL/RAMP commonly in many types (4, 31, 86, 175, 214, 247, 491, 508, 521, 552, 762 and 780) . DTL/RAMP as a molecular-target for breast cancer T Ueki et al of clinical cancers including bladder cancer, cholangiocarcinoma, lung cancers and renal cell carcinoma as well as breast cancers (data not shown). These results showed that this gene should serve as a valuable target for development of anticancer agents for a wide range of human cancers. Semiquantitative RT-PCR analysis Total RNAs were extracted from each of microdissected breast cancer clinical samples, microdissected normal breast ductal cells and breast cancer cell lines using RNeasy Micro Kits (Qiagen, Valencia, CA, USA), and polyA ( þ ) RNAs isolated from mammary gland purchased from Takara Clontech (Kyoto, Japan) as described previously (Nishidate et al., 2004) . Subsequently, T7-based amplification and reverse transcription were carried out as described previously (Nishidate et al., 2004) . We prepared appropriate dilutions of each single-stranded cDNA for subsequent PCR by monitoring Farnesyl-diphosphate farnesyltransferase 1 (FDFT1) as a quantitative control because these showed the smallest (relative ratio of breast cancer sample/normal control) fluctuations in our breast cancer-microarray data (Nishidate et al., 2004) . The primer sequences are listed in Supplementary  Table 1 .
Materials and methods
Breast cancer cell lines and clinical samples
Northern blot analysis
Northern blot membrane for breast cancer cell lines was prepared as described previously (Park et al., 2006) . Human multiple-tissue northern blots (Takara Clontech) were hybridized with [a 32 P]-dCTP-labeled PCR products of DTL/RAMP prepared by reverse transcription (RT)-PCR (see below). Prehybridization, hybridization and washing were performed according to the supplier's recommendations. The blots were autoradiographed with intensifying screens at À80 1C for 14 days. Specific probes (1,172bp) for DTL/RAMP were prepared by RT-PCR using the following primer set: 5 0 -GCA ATCTGCTATGTCAGCCAAC-3 0 and 5 0 -CAGGATCA GCTCAAA GTCTGACA-3 0 for DTL/RAMP.
Construction of expression vectors
To construct DTL/RAMP expression vectors, the entire coding sequence of DTL/RAMP cDNA was inserted into the NotI and XhoI sites of pCAGGSnHAc expression vector in frame with C-terminal HA-tag. Furthermore, to determine the phosphorylated regions of DTL/RAMP protein, we prepared the deletion constructs. For in vitro kinase assay, the entire coding sequence of DTL/RAMP cDNA fragment was cloned into the SmaI sites of pGEX-6P-1 expression vector (GE Healthcare, Buckinghamshire, UK). These constructs were confirmed by DNA sequencing (ABI3700; PE Applied Biosystems, Foster, CA, USA).
Generation of anti-DTL/RAMP polyclonal antibody Plasmid designed to express a part of DTL/RAMP (438-730 amino acids) with His-tag at its C-terminus was prepared using pET21 vector (Merck, Novagen, Madison, WI, USA). The recombinant peptide (36 kDa) was expressed in Escherichia coli, BL21 codon-plus (Stratagene, La Jolla, CA, USA), and purified using Ni-NTA resin (Qiagen) according to the supplier's protocol. The protein was inoculated into rabbits, and subsequently the immune sera were purified on antigen affinity columns using Affigel 15 gel (Bio-Rad, Hercules, CA, USA), according to supplier's instructions.
Western blot analysis
Cells were lysed with NP-40 lysis buffer (50 mM Tris-HCL (pH 8.0), 150 mM NaCL, 0.5% NP-40) including 0.1% protease inhibitor cocktail III (Calbiochem, San Diego, CA, USA). The proteins were mixed with SDS-sample buffer and boiled before loading at 10% SDS-polyacrylamide gel electrophoresis gel. After electrophoresis, the proteins were blotted onto nitrocellulose membrane (GE Healthcare), and blocked with 4% BlockAce solution (Dainippon Pharmaceutical, Osaka, Japan). The membranes were incubated with anti-DTL/ RAMP polyclonal antibody at 1:100 dilutions or anti-AURKB polyclonal antibody (Abcam, Cambridge, UK) at 1:100 dilutions. Finally the membrane was incubated with HRPconjugated secondary antibody and protein-bands were visualized by ECL (GE Healthcare).
l-Phosphatase assay T47D cells were lysed by NP-40 lysis buffer, and then were treated for 2 h at 30 1C with 400 units of l-phosphatase (New England Biolabs, Beverly, MA, USA) in phosphatase buffer containing 50 mM Tris-HCL (pH 7.5), 0.1 mM Na 2 -EDTA, 5 mM dithiothreitol, 2 mM MgCL 2 and 0.01% Brij-35. Furthermore, to define the phosphorylated site(s) of DTL/ RAMP protein, HEK293T cells were transiently transfected with pCAGGS-DTL-D1-HA, -D2-HA and -D3-HA, respectively, using FuGENE 6 (Roche, Basel, Switzerland) according to the manufacturer's instructions. Forty-eight hours after the transfection, the cells were lysed by NP-40 lysis buffer and then were treated with l-phosphatase (New England Biolabs) as described above.
Immunocytochemical staining HBC5 or T47D cells were fixed with phosphate-buffered saline (PBS)(À) containing 4% paraformaldehyde for 20 min, and rendered permeable with PBS(À) containing 0.1%. Triton X-100 at room temperature for 2 min. Subsequently, the cells were covered with 3% bovine serum albumin in PBS(À) for 1 h at room temperature to block nonspecific hybridization, and then were incubated with affinity-purified rabbit anti-DTL/ RAMP antibody at 1:100 dilutions or with anti-AURKB monoclonal antibody (Abcam) at 1:100 dilutions and anti-DTL/RAMP antibody at 1:100 dilution. After washing with PBS(À), cells were stained by an Alexa488-conjugated anti-rabbit secondary antibody (Molecular Probe, Eugene, OR, USA) at 1:1000 dilutions or an Alexa594-conjugated anti-mouse secondary antibody (Molecular Probe) at 1:1000 dilutions. Nuclei were counter-stained with 4 0 ,6 0 -diamidine-2 0 -phenylindole dihydrochloride (DAPI). Fluorescent images were obtained under a TCS SP2 AOBS microscope (Leica, Tokyo, Japan).
Immunohistochemical-staining analysis Slides of paraffin-embedded breast cancer specimens (sample nos. 010005T, MA05-317T, 010069T and 010571T), normal mammary tissue (sample no. 10441N), breast cancer tissuearrays (COSMOBIO, Tokyo, Japan) and other normal human tissues (lung, heart, liver, kidney, colon, pancreas, skeletal muscle, small intestine and testis; Biochain, Hayward, CA, USA) were processed for antigen retrieval by autoclave in accordance with the previous report (Shimo et al., 2007) . Tissue sections were incubated with anti-DTL/RAMP polyclonal antibody as primary antibody at 1:50 followed by horseradish peroxidase-cojugated secondary antibody (DakoCytomation, Carpinteria, CA, USA). Specific immunostaining was visualized with peroxidase substrate (3, 3 0 -diaminobenzidine tetrahydrochloride; DAKO liquid DAB chromogen; DakoCytomation). Finally, tissue specimens were stained with hematoxylin to discriminate nucleus from cytoplasm.
Fluorescence-activated cell sorting analysis T47D cells were synchronized their cell cycle by treatment with 0.5 mg/ml of aphidicolin (Sigma-Aldrich Japan KK, Tokyo, Japan) for 16 h. Subsequently, the cells were collected every 3 h up to 30 h, and fixed with 70% ethanol, and then kept at 4 1C until their use. The cells were incubated with 10 mg/ml RNaseI in PBS at 37 1C for 30 min and stained with 50 mg of propidium iodide at room temperature for 30 min. The cell suspensions at each time-point were analysed with FACscan (Becton Dickinson, Franklin Lakes, NJ, USA). Additionally, to examine expression levels of endogenous DTL/RAMP protein in each cell-cycle phase, we performed western blot at every 3 h using anti-DTL/RAMP polyclonal antibody. Furthermore, to examine the phosphorylation status of DTL/RAMP after mitotic phase in more detail, we synchronized T47D breast cancer cells with treatment of 0.15 mg/ml nocodazole for 18 h, and harvested mitotic cells at each time point (0, 60, 75, 90, 105, 120, 240, 360, 720 and 2880 min) by mitotic shake-off methods (Dechat et al., 1998) . We confirmed the phosphorylation of DTL/RAMP in T47D breast cancer cells at prometaphase by l-phosphatase assay described above.
Gene-silencing effect by small interfering RNA We had previously established a vector-based RNAi expression system using psiU6BX3.0 siRNA expression vector (Shimokawa et al., 2003) . The siRNA expression vectors against DTL/RAMP (psiU6BX3.0-DTL/RAMP) and EGFP (psiU6BX3.0-EGFP) as a negative control were prepared as described previously (Park et al., 2006) . The target sequence of synthetic oligonucleotides for siRNA were as follows: si no. 1, 5 0 -GATCATGTCTCCGAGAAAA-3 0 ; si no. 2, 5 0 -GGAAGC CATAGAATTGCTC-3 0 ; siEGFP, 5 0 -GAAGCAGCACGAC TTCTTC-3 0 . Each siRNA expression vector was transfected with FuGENE6 (Roche) into T47D or HBC4 and these cells were cultured with a medium containing 0.7 or 0.4 mg/ml of neomycin (Geneticin; Invitrogen, Carlsbad, CA, USA) for 7 days. Cell growth was analysed by MTT assay and colonyformation assay as described previously (Park et al., 2006) . Furthermore, we used siRNA oligonucleotides (Sigma-Aldrich Japan KK) due to its high transfection efficiency to further verify the knockdown effects of DTL/RAMP and AURKB on cell morphology. The sequences targeting each gene were as follows: siDTL/RAMP, 5 0 -ACUCCUACGUUCUCUAUUA-3 0 ; siAURKB, 5 0 -AAGGUGAUGGAGAAUAGCAGU-3 0 ; siEGFP (control), 5 0 -GCAGCACGACUUCUUCAAG-3 0 . T47D cells were transfected with those siRNAs using Lipofectamin RNAiMAX (Invitrogen) in Optimem (Invitrogen) medium according to the instructions of manufacture. After 96 h, we confirmed knockdown effect of DTL/RAMP and AURKB by western blot analysis and semiquantitative RT-PCR analyses as described above. Moreover, morphological changes of the T47D and HBC4 cells were observed by microscopy and by immunocytochemical-staining analysis using AlexaFluor594 Phalloidin (Molecular Probe) and DTL/RAMP polyclonal antibody. To evaluate the effect of DTL/RAMP depletion on cell cycle by siRNA, we performed FACS analysis 72 h after the transfection of siRNA according to the method described above.
Establishment of NIH3T3 cells stably expressing DTL/RAMP Flag-tagged DTL/RAMP expression vector (pCAGGSn3FC-DTL/RAMP) or mock vector (pCAGGSn3FC) was transfected into NIH3T3 cells using FuGENE6 (Roche), and then incubated in the culture medium containing 0.9 mg/ml. of neomycin (geneticin; Invitrogen). Three weeks later, we established four independent DTL/RAMP stably expressing clones and designated them as follows: NIH3T3-DTL/RAMP-1, -2, -3 and 4, and NIH3T3-Mock-1, -2 and -3. For growth assay, 5000 cells of each of DTL/RAMP-expressing transformant or Mock-transformant as a control was seeded. Cell viability was quantified with MTT assay every day.
Statistical analysis
Statistical significance was calculated by Student's t-test, using Statview 5.0 software (SAS Institute, Cary, NC, USA). A difference of Po0.05 was considered to be statistically significant.
Co-immunoprecipitation and western blot analyses T47D cells were lysed in immunoprecipitation buffer (50 mM Tris-HCL (pH 7.5), 150 mM NaCL, 0.5% NP-40, 50 mM NaF, 1 mM NaVO 3 and 1 mM DTT) in the presence of protease inhibitor (Calbiochem). Cell lysate was precleared by incubation in 750 ml of protein G-agarose beads with 7.5 mg of normal mouse immunoglobulin G (IgG) at 4 1C for 3 h. The supernatants were incubated at 4 1C with 30 mg of anti-DTL/RAMP rabbit polyclonal antibody or rabbit normal IgG for 1 h, and then 100 ml of protein G-agarose beads were added. After the beads were collected from each sample and washed five times with 1 ml of immunoprecipitation buffer, they were eluted by 30 ml of Laemmli sample buffer and boiled for 5 min.
In vitro kinase assay One microgram of wild type or kinase-dead (D200A) of AURKB (Upstate, Temecula, CA, USA) was incubated in 20 ml kinase assay buffer (50 mM Tris-HCL (pH 7.5), 10 mM MgCL 2 , 2mM dithiothreitol, 1 mM EGTA, 0.01% Brij35, 500 mM ATP), and then supplemented with 5 mCi of [ 32 P-g] ATP (GE Healthcare). For the substrate, we added 1 mg of the full length of DTL/RAMP (1-730 amino acids) recombinant protein into the reaction solutions. After 10 min incubation at 30 1C, the reactions were terminated by addition of SDS sample buffer.
